Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04970368 | Comparison of Nodal Staging in Endometrial Cancer | terminated | Phase 3 | 38 | Frederick R. Ueland, M.D.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin | terminated | Phase 3 | 16 | GlaxoSmithKlineINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04329949 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(RELIANT) |
| terminated |
| Phase 3 |
| 43 |
| Corcept TherapeuticsINDUSTRY |
| 1 |
| Nov 18, 2023 |
| clinicaltrials |
| NCT02826161 | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer(CanStem43L) | terminated | Phase 3 | 4 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | terminated | Phase 2 / Phase 3 | 309 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Nov 14, 2023 | clinicaltrials |
| NCT03786094 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer(FORTRESS) | terminated | Phase 3 | 432 | Spexis AGINDUSTRY | 13 | Nov 1, 2023 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer(AXLerate-OC) | terminated | Phase 3 | 366 | Aravive, Inc.INDUSTRY | 11 | Oct 30, 2023 | clinicaltrials |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | terminated | Phase 3 | 20 | Mersana TherapeuticsINDUSTRY | 3 | Oct 26, 2023 | clinicaltrials |
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS(THRIVE) | terminated | Phase 2 / Phase 3 | 1 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02204982 | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma(DYNAMO + R) | terminated | Phase 3 | 13 | SecuraBioINDUSTRY | 4 | Sep 28, 2023 | clinicaltrials |
| NCT04385433 | A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer(PRAVAPREV-01) | terminated | Phase 3 | 15 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 2 | Aug 24, 2023 | clinicaltrials |
| NCT01011478 | Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery | terminated | Phase 3 | 406 | NSABP Foundation IncNETWORK | 2 | Aug 16, 2023 | clinicaltrials |
| NCT05106335 | A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC | terminated | Phase 3 | 1 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | terminated | Phase 3 | 96 | Gilead SciencesINDUSTRY | 10 | Aug 14, 2023 | clinicaltrials |
| NCT00352079 | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | terminated | Phase 3 | 41 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00651326 | Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer(DART) | terminated | Phase 3 | 48 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00658593 | Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer | terminated | Phase 3 | 19 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03024996 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy(IMmotion010) | terminated | Phase 3 | 778 | Hoffmann-La RocheINDUSTRY | 28 | Aug 3, 2023 | clinicaltrials |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | terminated | Phase 3 | 3,131 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | terminated | Phase 3 | 355 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Jul 6, 2023 | clinicaltrials |
| NCT00002525 | Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed | terminated | Phase 3 | 859 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02450331 | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection(IMvigor010) | terminated | Phase 3 | 809 | Hoffmann-La RocheINDUSTRY | 24 | Jun 18, 2023 | clinicaltrials |
| NCT04649060 | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma(LIGHTHOUSE) | terminated | Phase 3 | 54 | Oncopeptides ABINDUSTRY | 11 | Jun 8, 2023 | clinicaltrials |
| NCT04763135 | Mirtazapine in Cancer-related Poly-symptomatology(MIR-P) | terminated | Phase 3 | 1 | Hospices Civils de LyonOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT03152929 | Paravertebral Block (PVC) Versus Pectoral Nerve Block (PEC) | terminated | Phase 3 | 89 | Corewell Health WestOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT02516696 | BiRd vs. Rd as Initial Therapy in Multiple Myeloma(BiRd vs Rd) | terminated | Phase 3 | 12 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | terminated | Phase 3 | 773 | NuCana plcOTHER | 15 | May 24, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | terminated | Phase 3 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT00444093 | Prospective Randomized Open Label Study of the Treatment of Therapy-associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium -(Loop) | terminated | Phase 3 | 1 | Philipps University MarburgOTHER | 0 | May 11, 2023 | clinicaltrials |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. | terminated | Phase 3 | 80 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | terminated | Phase 3 | 93 | BayerINDUSTRY | 9 | May 3, 2023 | clinicaltrials |
| NCT00272987 | ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | terminated | Phase 3 | 63 | Novartis PharmaceuticalsINDUSTRY | 2 | Apr 28, 2023 | clinicaltrials |
| NCT03495921 | A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide(VITA) | terminated | Phase 3 | 32 | Gradalis, Inc.INDUSTRY | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05001724 | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent | terminated | Phase 2 / Phase 3 | 16 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence(PIVOT-12) | terminated | Phase 3 | 765 | Nektar TherapeuticsINDUSTRY | 17 | Apr 21, 2023 | clinicaltrials |
| NCT00004935 | Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | terminated | Phase 3 | 175 | Swiss Cancer InstituteOTHER | 2 | Apr 18, 2023 | clinicaltrials |
| NCT03642132 | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | terminated | Phase 3 | 79 | PfizerINDUSTRY | 10 | Apr 6, 2023 | clinicaltrials |
| NCT03354611 | Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging | terminated | Phase 2 / Phase 3 | 21 | Koning CorporationINDUSTRY | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02438007 | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC(ARMOR3-SV) | terminated | Phase 3 | 953 | LTN PHARMACEUTICALS, INC.INDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT02853604 | Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer(AIM2CERV) | terminated | Phase 3 | 110 | Advaxis, Inc.INDUSTRY | 14 | Mar 14, 2023 | clinicaltrials |
| NCT00543127 | Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole | terminated | Phase 3 | 870 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT03921996 | Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer | terminated | Phase 3 | 57 | Swiss Cancer InstituteOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | terminated | Phase 3 | 38 | Timothy HoffmanFED | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03678428 | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | terminated | Phase 3 | 92 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 5, 2024source: clinicaltrials